Nycomed buys majority in Chinese Guangdong Techpool Bio-Pharma.
Swiss pharmaceuticals company Nycomed said Monday it has bought a controlling stake of 51.34% in Chinese biopharmaceutical firm Guangdong Techpool Bio-Pharma Co Ltd for an undisclosed sum and in a move to strengthen Chinese activities.
Guangdong Techpool focuses on the development of biologic drugs from natural sources. It has launched a broad-acting trypsin inhibitor, used in sepsis and multiple organ dysfunctions treatment. The company's products are exported to Japan and South Korea.
Shanghai Pharmaceutical Group, the previous majority owner of Guangdong Techpool, will control 40.8% in the company.Country: China, Sector: PharmaceuticalsTarget: Guangdong Techpool Bio-Pharma Co LtdBuyer: Nycomed International Management GmbHVendor: Shanghai Pharmaceutical GroupType: Corporate acquisitionStatus: Closed
|Printer friendly Cite/link Email Feedback|
|Publication:||M & A Navigator|
|Date:||Nov 2, 2010|
|Previous Article:||Canadian Day4 Energy closes German ACI takeover.|
|Next Article:||Advent takes over drilling fluid treatment firm BOS.|